Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)
Status:
Terminated
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine how safe and effective fondaparinux is in treating
patients with suspected or confirmed heparin-induced thrombocytopenia (HIT).
Phase:
Phase 2
Details
Lead Sponsor:
James Graham Brown Cancer Center University of Louisville
Collaborators:
James Graham Brown Cancer Center University of Louisville